Related Experiment Video
Updated: Feb 20, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Ral signaling pathway in health and cancer
Adel Rezaei Moghadam1, Elham Patrad2, Elham Tafsiri3
1Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada.
Abstract:
The Ral (Ras-Like) signaling pathway plays an important role in the biology of cells. A plethora of effects is regulated by this signaling pathway and its prooncogenic effectors. Our team has demonstrated the overactivation of the RalA signaling pathway in a number of human malignancies including cancers of the liver, ovary, lung, brain, and malignant peripheral nerve sheath tumors. Additionally, we have shown that the activation of RalA in cancer stem cells is higher in comparison with differentiated cancer cells. In this article, we review the role of Ral signaling in health and disease with a focus on the role of this multifunctional protein in the generation of therapies for cancer. An improved understanding of this pathway can lead to development of a novel class of anticancer therapies that functions on the basis of intervention with RalA or its downstream effectors.
Insights
The RalA signaling pathway is overactivated in many human cancers, particularly in cancer stem cells. Targeting this pathway offers a promising strategy for novel cancer therapies.
Area of Science:
- Cellular biology
- Oncology
- Molecular signaling
Background:
- The Ral (Ras-Like) signaling pathway regulates diverse cellular processes.
- Aberrant signaling contributes to oncogenesis.
- RalA is a key prooncogenic effector in this pathway.
Purpose of the Study:
- To review the role of Ral signaling in cellular biology and disease.
- To focus on RalA's role in cancer generation and therapeutic strategies.
Main Methods:
- Literature review of Ral signaling pathways.
- Analysis of RalA overactivation in various human malignancies.
- Comparison of RalA activation in cancer stem cells versus differentiated cancer cells.
Main Results:
- RalA signaling is overactivated in liver, ovarian, lung, brain cancers, and malignant peripheral nerve sheath tumors.
- RalA activation is significantly higher in cancer stem cells compared to differentiated cancer cells.
Conclusions:
- Ral signaling, particularly RalA, is a critical player in cancer development.
- Understanding RalA's function can lead to novel anticancer therapies targeting this pathway or its effectors.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Canonical Wnt Signaling Pathway
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway

